Press release
Exocrine Pancreatic Insufficiency (EPI) Market New Product Development & Latest Trends
Exocrine Pancreatic Insufficiency (EPI) Market
Exocrine Pancreatic Insufficiency (EPI) is a chronic digestive condition where the pancreas fails to produce enough enzymes to properly digest food. This leads to symptoms such as steatorrhea (fatty stools), weight loss, bloating, abdominal pain, and nutritional deficiencies. EPI is most often caused by chronic pancreatitis, cystic fibrosis, pancreatic cancer, and gastrointestinal surgery, with a growing patient pool due to the global rise in gastrointestinal and metabolic disorders.
The mainstay of treatment is Pancreatic Enzyme Replacement Therapy (PERT), alongside dietary modifications and supportive care. Increasing disease awareness, earlier diagnosis, and new PERT formulations are fueling market expansion.
In 2024, the global Exocrine Pancreatic Insufficiency Market is valued at USD 4.2 billion and is projected to reach USD 8.3 billion by 2034, growing at a CAGR of 7.1% during 2025-2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71112
Market Overview
• Market Size 2024: USD 4.2 billion
• Forecast 2034: USD 8.3 billion
• CAGR (2025-2034): 7.1%
• Key Drivers: Rising prevalence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer; growing adoption of PERT; and increasing physician awareness.
• Key Challenges: High cost of long-term enzyme therapy, underdiagnosis in developing regions, and limited awareness among primary care providers.
• Leading Players: AbbVie, Viatris, Nordmark Arzneimittel, Allergan, Janssen Pharmaceuticals, Chiesi Farmaceutici, Cipla, Dr. Reddy's Laboratories, Sun Pharma, Alcresta Therapeutics.
The market remains enzyme therapy-driven, but innovations in diagnostics and patient monitoring are opening new opportunities.
Segmentation Analysis
By Product
• Pancreatic Enzyme Replacement Therapy (PERT) formulations (lipase, amylase, protease combinations)
• Nutritional supplements
• Diagnostics (imaging, stool elastase test kits)
• Supportive care products
By Therapy
• Pharmacological therapy (PERT)
• Nutritional therapy
• Combination therapy
• Experimental therapies
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Specialty clinics
• Online pharmacies
By End-Use
• Hospitals
• Gastroenterology clinics
• Research institutes
• Homecare
By Application
• Chronic pancreatitis-induced EPI
• Cystic fibrosis-related EPI
• Pancreatic cancer-related EPI
• Post-surgical EPI
• Other gastrointestinal disorders
Summary of Segmentation
The PERT segment dominates, accounting for the majority of market revenue, while diagnostic kits and online pharmacies are expected to grow at the fastest pace due to increasing demand for early detection and convenient therapy access.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71112/exocrine-pancreatic-insufficiency-market
Regional Analysis
• North America: Largest market share, supported by advanced diagnostics, strong adoption of PERT, and high awareness among gastroenterologists.
• Europe: Strong growth driven by cystic fibrosis programs, reimbursement policies, and expansion of PERT formulations.
• Asia-Pacific: Fastest-growing region (CAGR >8%), driven by rising prevalence of chronic pancreatitis and pancreatic cancer, healthcare modernization, and growing awareness.
• Middle East & Africa: Moderate growth due to limited diagnosis and affordability issues, though rare disease programs are improving access.
• Latin America: Brazil and Mexico lead growth, supported by healthcare improvements and better diagnostic capabilities.
Regional Trends Summary
While North America and Europe dominate today, Asia-Pacific is emerging as the fastest-growing region, owing to its large patient base and rising healthcare investments.
Market Dynamics
Key Growth Drivers
• Rising prevalence of chronic pancreatitis, pancreatic cancer, and cystic fibrosis.
• Expanding use of PERT formulations as the gold standard of care.
• Increasing global awareness and earlier diagnosis.
• Growing use of nutritional supplements and digital monitoring tools.
Key Challenges
• Underdiagnosis due to non-specific symptoms.
• High cost of lifelong PERT for patients in low-income countries.
• Limited availability of specialized gastroenterology care in rural regions.
• Dependence on lifelong treatment without curative solutions.
Latest Trends
• Development of next-generation PERT formulations with improved stability and dosing.
• Expansion of point-of-care diagnostic tools such as stool elastase kits.
• Integration of digital health and telemedicine for EPI management.
• Clinical research into microbiome-modulating therapies as adjuncts to PERT.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71112
Competitive Landscape
Major Players
• AbbVie
• Viatris
• Nordmark Arzneimittel
• Allergan
• Janssen Pharmaceuticals
• Chiesi Farmaceutici
• Cipla
• Dr. Reddy's Laboratories
• Sun Pharma
• Alcresta Therapeutics
Competitive Insights
The EPI market is moderately consolidated, with AbbVie leading through its Creon (PERT) brand. Viatris and Nordmark also have strong market shares in enzyme formulations. Emerging biotech firms like Alcresta Therapeutics are focusing on innovative delivery methods and adjunct therapies. Strategic collaborations, licensing deals, and expanded regional distribution remain central to competition.
Conclusion
The global Exocrine Pancreatic Insufficiency Market is on a strong upward trajectory. From USD 4.2 billion in 2024 to USD 8.3 billion by 2034, the market will grow at a CAGR of 7.1%, fueled by the adoption of enzyme therapy, increasing prevalence of pancreatic disorders, and advances in diagnostics.
• Opportunities: Asia-Pacific growth, next-generation enzyme formulations, and digital patient management.
• Challenges: Underdiagnosis, affordability barriers, and lack of curative therapies.
• Key Takeaway: Companies that focus on innovative PERT formulations, affordable therapy models, and global screening programs will lead the EPI market in the next decade.
This report is also available in the following languages : Japanese (外分泌膵機能不全市場), Korean (외분비 췌장 부전 시장), Chinese (胰腺外分泌功能不全市场), French (Marché de l'insuffisance pancréatique exocrine), German (Markt für exokrine Pankreasinsuffizienz), and Italian (Mercato dell'insufficienza pancreatica esocrina), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71112
Our More Reports:
Short Bowel Syndrome Market
https://exactitudeconsultancy.com/reports/71128/short-bowel-syndrome-market
Autoimmune Gastritis Market
https://exactitudeconsultancy.com/reports/71130/autoimmune-gastritis-market
Chronic Idiopathic Constipation Market
https://exactitudeconsultancy.com/reports/71132/chronic-idiopathic-constipation-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exocrine Pancreatic Insufficiency (EPI) Market New Product Development & Latest Trends here
News-ID: 4158135 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for PERT
Is PEX or PERT better for underfloor heating?
When deciding between PEX (cross-linked polyethylene) and PERT (polyethylene of raised temperature resistance) pipes for underfloor heating systems, it's essential to weigh their properties, installation methods, costs, and durability. Both materials are widely used in modern underfloor heating systems, but they have distinct characteristics that make them suitable for different scenarios.
Overview of PEX and PERT Pipes
PEX pipes are made from cross-linked polyethylene, a durable material created by chemically altering polyethylene…
N-PERT Cell Market Analysis and Future Prospects for 2030
The world of the n-pert cell market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing environment.…
India Home Automation Market By Leading Key Players, Opportunities and Strategie …
Allied Market Research published a new report, titled, India Home Automation Market: Global Opportunity Analysis and Industry Forecast, 2021-2026.
The latest study on the Global India Home Automation Market covers a wide range of organizations from different regions. It offers a comprehensive information based on market developments, competitions, and challenges faced by the industry. With this, the report also involves the key strategies followed among the market players, major market determinants,…
Home Automation Market Size India Expansion by Top Players Profile Overview by 2 …
The India home automation market size was valued at $1,790.9 million in 2018, and is expected to reach $13,574.1 million by 2026, growing at a CAGR of 29.8% during the forecast period 2019-2026. Home automation systems in India have witnessed an unprecedented demand in the recent years, due to increased concerns about safety & security, especially in urban areas.
Moreover, factors such as improved lifestyle, increase in disposable income of…
India Home Automation Market Key Players| Fueblabs, Larsen & Toubro, Schneider, …
A Comprehensive research study conducted by KD Market Insights on " India Home Automation Market - By Product Type (Lighting, Security And Safety, HVAC, Entertainment, and Others), Technology (Wired, and Wireless), and End-User (Residential, Commercial, and Hospitality): Opportunity Analysis and Industry Forecast, 2019–2026 " report offers extensive and highly detailed historical, current and future market trends in the India and regional/market. The India Home Automation Market report includes market size,…
Exocrine Pancreatic Insufficiency Market Report 2018: Segmentation by Type (Nutr …
Global Exocrine Pancreatic Insufficiency market research report provides company profile for Cilian, Nordmark Arzneimittel, Laboratoires Mayoly Spindler, Axcan Pharma, Aptalis Pharma, Eli Lilly and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report…
